{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:46:14Z","timestamp":1790660774110,"version":"4.1.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clgc.2025.102478","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T16:05:09Z","timestamp":1764432309000},"page":"102478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Urothelial Carcinoma In Situ: Advances in Diagnosis and Management"],"prefix":"10.1016","volume":"24","author":[{"given":"Gabriele","family":"Ricciardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Tralongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pierconti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Zuccal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagiovanna","family":"Ballato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ieni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rossanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Ficarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Fadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6260-6310","authenticated-orcid":false,"given":"Maurizio","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102478_bib0001","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2025.102478_bib0002","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.eururo.2013.10.001","article-title":"International variations in bladder cancer incidence and mortality","volume":"66","author":"Chavan","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0003","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.eururo.2014.10.040","article-title":"Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review","volume":"67","author":"Casey","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0004","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/PAP.0000000000000239","article-title":"Urothelial carcinoma in situ (CIS): new insights","volume":"26","author":"Akhtar","year":"2019","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.clgc.2025.102478_bib0005","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S1078-1439(99)00020-4","article-title":"Updated concepts and treatment of carcinoma in situ","volume":"4","author":"Lamm","year":"1998","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102478_bib0006","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eururo.2016.03.011","article-title":"Pathology and genetics: tumours of the urinary system and male genital system: clinical implications of the 4th edition of the WHO Classification and beyond","volume":"70","author":"Montironi","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0007","doi-asserted-by":"crossref","unstructured":"M Moschini, F Soria, M Susani, et al. Impact of the level of urothelial carcinoma involvement of the prostate on survival after radical cystectomy, Bladder Cancer 3 161-69. https:\/\/doi.org\/10.3233\/BLC-160086.","DOI":"10.3233\/BLC-160086"},{"key":"10.1016\/j.clgc.2025.102478_bib0008","doi-asserted-by":"crossref","first-page":"48","DOI":"10.6004\/jnccn.2009.0004","article-title":"Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis","volume":"7","author":"Nese","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2025.102478_bib0009","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1586\/era.10.73","article-title":"The origins of urothelial carcinoma","volume":"10","author":"Cheng","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clgc.2025.102478_bib0010","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.1158\/1078-0432.CCR-05-0891","article-title":"Molecular evidence supporting field effect in urothelial carcinogenesis","volume":"11","author":"Jones","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2025.102478_bib0011","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0012","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0013","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.euf.2019.03.012","article-title":"Carcinoma In situ of the urinary bladder: a systematic review of current knowledge regarding detection, treatment, and outcomes","volume":"6","author":"Subiela","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2025.102478_bib0014","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1756287215599694","article-title":"Management of carcinoma in situ of the bladder: best practice and recent developments","volume":"7","author":"Tang","year":"2015","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0015","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0016","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2011.1142","article-title":"Association between smoking and risk of bladder cancer among men and women","volume":"306","author":"Freedman","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2025.102478_sbref0017","series-title":"How Tobacco Smoke Causes Disease: the Biology and Behavioral Basis for Smoking-Attributable Disease: a Report of the Surgeon General","year":"2010"},{"key":"10.1016\/j.clgc.2025.102478_bib0018","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0019","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.2147\/CMAR.S175062","article-title":"Secondhand smoking increases bladder cancer risk in nonsmoking population: a meta-analysis","volume":"10","author":"Yan","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clgc.2025.102478_bib0020","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/oem.58.9.590","article-title":"Occupational risk factors for male bladder cancer: results from a population based case cohort study in the Netherlands","volume":"58","author":"Zeegers","year":"2001","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.clgc.2025.102478_bib0021","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.clgc.2025.102478_bib0022","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/jnci\/djm004","article-title":"Fifty-year study of lung and bladder cancer mortality in chile related to arsenic in drinking water","volume":"99","author":"Marshall","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2025.102478_bib0023","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3109\/07357900009038249","article-title":"Arsenic in drinking water and bladder cancer","volume":"18","author":"Steinmaus","year":"2000","journal-title":"Cancer Invest"},{"key":"10.1016\/j.clgc.2025.102478_bib0024","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1442-2042.2008.02194.x","article-title":"Japanese Urological Association, bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association","volume":"16","author":"Hinotsu","year":"2009","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0025","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2025.102478_bib0026","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1097\/00005392-199805000-00022","article-title":"The molecular characteristics of bladder cancer in young patients","volume":"159","author":"Linn","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0027","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2217\/pme.11.15","article-title":"Genetic susceptibility to bladder cancer risk and outcome","volume":"8","author":"Gu","year":"2011","journal-title":"Per Med"},{"key":"10.1016\/j.clgc.2025.102478_bib0028","doi-asserted-by":"crossref","unstructured":"N Rothman, M Garcia-Closas, N Chatterjee, et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci, Nat Genet 42 (2010) 978-84. https:\/\/doi.org\/10.1038\/ng.687.","DOI":"10.1038\/ng.687"},{"key":"10.1016\/j.clgc.2025.102478_bib0029","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/ng.229","article-title":"Sequence variant on 8q24 confers susceptibility to urinary bladder cancer","volume":"40","author":"Kiemeney","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.clgc.2025.102478_bib0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10555-009-9190-y","article-title":"Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications","volume":"28","author":"Wu","year":"2009","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.clgc.2025.102478_bib0031","first-page":"65","article-title":"Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis","volume":"506-507","author":"Hein","year":"2002","journal-title":"Mutat Res"},{"key":"10.1016\/j.clgc.2025.102478_bib0032","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0140-6736(05)67137-1","article-title":"NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish bladder cancer study and meta-analyses","volume":"366","author":"Garc\u00eda-Closas","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2025.102478_bib0033","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.mrgentox.2004.11.012","article-title":"Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians","volume":"581","author":"Gu","year":"2005","journal-title":"Mutat Res"},{"key":"10.1016\/j.clgc.2025.102478_sbref0034","series-title":"GeneReviews\u00ae","article-title":"HRAS-related Costello syndrome","author":"Gripp","year":"1993"},{"key":"10.1016\/j.clgc.2025.102478_bib0035","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/jmg.2010.076992","article-title":"Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers","volume":"47","author":"van der Post","year":"2010","journal-title":"J Med Genet"},{"key":"10.1016\/j.clgc.2025.102478_bib0036","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1897-4287-8-6","article-title":"Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients","volume":"8","author":"Riegert-Johnson","year":"2010","journal-title":"Hered Cancer Clin Pract"},{"key":"10.1016\/j.clgc.2025.102478_bib0037","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1056\/NEJM199411103311903","article-title":"Accumulation of nuclear p53 and tumor progression in bladder cancer","volume":"331","author":"Esrig","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102478_bib0038","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919890285","article-title":"Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors","volume":"11","author":"Casadei","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clgc.2025.102478_bib0039","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1470-2045(05)70315-6","article-title":"P53 as a prognostic marker for bladder cancer: a meta-analysis and review","volume":"6","author":"Malats","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102478_bib0040","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/j.1464-410X.2009.08838.x","article-title":"Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract","volume":"104","author":"Colin","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2025.102478_bib0041","first-page":"45","article-title":"Aristolochic acids","volume":"12","year":"2011","journal-title":"Rep Carcinog"},{"key":"10.1016\/j.clgc.2025.102478_bib0042","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.eururo.2018.09.034","article-title":"External beam radiotherapy increases the risk of bladder cancer when compared with radical prostatectomy in patients affected by prostate cancer: a population-based analysis","volume":"75","author":"Moschini","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0043","first-page":"1","article-title":"Pharmaceuticals","volume":"100","year":"2012","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"key":"10.1016\/j.clgc.2025.102478_bib0044","first-page":"65","article-title":"Prevention and control of schistosomiasis: a current perspective","volume":"2014","author":"Inobaya","year":"2014","journal-title":"Res Rep Trop Med"},{"key":"10.1016\/j.clgc.2025.102478_bib0045","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1128\/CMR.12.1.97","article-title":"Relationship between schistosomiasis and bladder cancer","volume":"12","author":"Mostafa","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.clgc.2025.102478_bib0046","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-9378-8-19","article-title":"Schistosomiasis and urinary bladder cancer in North Western Tanzania: a retrospective review of 185 patients","volume":"8","author":"Rambau","year":"2013","journal-title":"Infect Agent Cancer"},{"key":"10.1016\/j.clgc.2025.102478_bib0047","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jnci.2012.08.002","article-title":"Bladder cancer and schistosomiasis","volume":"24","author":"Zaghloul","year":"2012","journal-title":"J Egypt Natl Canc Inst"},{"key":"10.1016\/j.clgc.2025.102478_bib0048","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S0022-5347(01)67650-X","article-title":"Carcinoma in situ of the bladder","volume":"153","author":"Hudson","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0049","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.critrevonc.2010.01.005","article-title":"Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art","volume":"76","author":"Williamson","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2025.102478_bib0050","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/pgmj.2006.050112","article-title":"Importance of red patches diagnosed in cystoscopy for haematuria and lower urinary tract symptoms","volume":"83","author":"Fernando","year":"2007","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.clgc.2025.102478_bib0051","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.eururo.2003.11.019","article-title":"Biopsy of the red patch at cystoscopy: is it worthwhile?","volume":"45","author":"Swinn","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0052","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1097\/PAS.0000000000001318","article-title":"Carcinoma In situ with plasmacytoid features: a clinicopathologic study of 23 cases","volume":"43","author":"Sangoi","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2025.102478_bib0053","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pathol.2020.10.001","article-title":"Urothelial carcinoma in situ: diagnostic update","volume":"53","author":"McKenney","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.clgc.2025.102478_bib0054","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00428-013-1378-4","article-title":"Different subtypes of carcinoma in situ of the bladder do not have a different prognosis","volume":"462","author":"Comp\u00e9rat","year":"2013","journal-title":"Virchows Arch"},{"key":"10.1016\/j.clgc.2025.102478_bib0055","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.acuro.2017.10.001","article-title":"Clinical usefulness of random biopsies in diagnosis and treatment of non-muscle invasive bladder cancer: systematic review and meta-analysis","volume":"42","author":"Subiela","year":"2018","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"10.1016\/j.clgc.2025.102478_bib0056","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.eururo.2007.12.006","article-title":"Urinary markers in bladder cancer","volume":"53","author":"Vrooman","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0057","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0058","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000019859","article-title":"Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee","volume":"35","author":"van der Meijden","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0059","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1442-2042.2012.03211.x","article-title":"Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"20","author":"Li","year":"2013","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170819","article-title":"A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer","volume":"12","author":"Xiong","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.clgc.2025.102478_bib0061","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.eururo.2009.11.041","article-title":"Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies","volume":"57","author":"Kausch","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0062","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1017\/S0266462310001364","article-title":"Aberdeen technology assessment review (TAR) Group, photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis","volume":"27","author":"Mowatt","year":"2011","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.clgc.2025.102478_bib0063","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.urolonc.2010.09.009","article-title":"Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder","volume":"30","author":"Lerner","year":"2012","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102478_bib0064","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","article-title":"Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data","volume":"64","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0065","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.eururo.2013.07.007","article-title":"Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature","volume":"64","author":"Rink","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0066","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00428-018-2354-9","article-title":"Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications","volume":"472","author":"Barth","year":"2018","journal-title":"Virchows Arch"},{"key":"10.1016\/j.clgc.2025.102478_bib0067","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.humpath.2020.02.008","article-title":"Immunohistochemical staining patterns of ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap","volume":"98","author":"Nguyen","year":"2020","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clgc.2025.102478_bib0068","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/his.13762","article-title":"Precursor lesions of the urinary bladder","volume":"74","author":"McKenney","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.clgc.2025.102478_bib0069","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5858\/arpa.2016-0411-OA","article-title":"CK20 and p53 immunohistochemical staining patterns in urinary bladder specimens with equivocal atypia","volume":"142","author":"Arias-Stella","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clgc.2025.102478_bib0070","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.clgc.2025.102478_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109179","article-title":"Multiomics profiling of urothelial carcinoma in situ reveals CIS-specific gene signature and immune characteristics","volume":"27","author":"Anurag","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.clgc.2025.102478_bib0072","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1101\/gr.197046.115","article-title":"APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication","volume":"26","author":"Seplyarskiy","year":"2016","journal-title":"Genome Res"},{"key":"10.1016\/j.clgc.2025.102478_bib0073","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2022.09.008","article-title":"Elevated T-cell exhaustion and urinary tumor DNA levels are associated with Bacillus Calmette-Gu\u00e9rin failure in patients with non-muscle-invasive bladder cancer","volume":"82","author":"Strandgaard","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0074","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1186\/s12885-021-08372-9","article-title":"Significance of KDM6A mutation in bladder cancer immune escape","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2025.102478_bib0075","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2025.102478_bib0076","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/curroncol31020079","article-title":"BCG and alternative therapies to BCG therapy for non-muscle-invasive bladder cancer","volume":"31","author":"Lidagoster","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clgc.2025.102478_bib0077","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s11255-023-03638-6","article-title":"Bladder perforation as a complication of transurethral resection of bladder tumors: the predictors, management, and its impact in a series of 1570 at a tertiary urology institute","volume":"55","author":"Osman","year":"2023","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.clgc.2025.102478_bib0078","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.euo.2022.05.001","article-title":"En bloc versus conventional transurethral resection of bladder tumors: a single-center prospective randomized noninferiority trial","volume":"5","author":"Gallioli","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102478_bib0079","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ITT.S202006","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) therapy for bladder cancer: an update","volume":"9","author":"Guallar-Garrido","year":"2020","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.clgc.2025.102478_bib0080","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0081","first-page":"65","article-title":"Immunotherapy for bladder cancer","volume":"7","author":"Fuge","year":"2015","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0082","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0090-4295(01)00921-9","article-title":"Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2025.102478_bib0083","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrurol.2015.58","article-title":"Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer","volume":"12","author":"Kamat","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0084","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000049765","article-title":"Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861","volume":"40","author":"Jakse","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0085","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.urology.2020.10.039","article-title":"Side effects of intravesical BCG and chemotherapy for bladder cancer: what they are and how to manage them","volume":"149","author":"Koch","year":"2021","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2025.102478_bib0086","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) treatment\u2019s severe complications: a single institution review of incidence, presentation and treatment outcome","volume":"19","author":"Waked","year":"2020","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.clgc.2025.102478_bib0087","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1442-2042.2006.01257.x","article-title":"Epididymo-orchitis caused by intravesically instillated bacillus Calmette-Gu\u00e9rin: genetically proven using a multiplex polymerase chain reaction method","volume":"13","author":"Harada","year":"2006","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0088","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/RCT.0b013e3182aac58a","article-title":"Changes observed in multiparametric prostate magnetic resonance imaging characteristics correlate with histopathological development of chronic granulomatous prostatitis after intravesical Bacillus Calmette-Guerin therapy","volume":"38","author":"Logan","year":"2014","journal-title":"J Comput Assist Tomogr"},{"key":"10.1016\/j.clgc.2025.102478_bib0089","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0022-5347(17)41803-9","article-title":"Granulomatous prostatitis following Bacillus Calmette-Guerin immunotherapy of bladder cancer","volume":"140","author":"Oates","year":"1988","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejvsvf.2023.02.003","article-title":"BCG aortitis, a rare complication of BCG therapy","volume":"58","author":"Haddad","year":"2023","journal-title":"EJVES Vasc Forum"},{"key":"10.1016\/j.clgc.2025.102478_bib0091","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.juro.2015.08.075","article-title":"Randomized controlled study of the efficacy, safety and quality of life with low dose Bacillus Calmette-Gu\u00e9rin instillation therapy for nonmuscle invasive bladder cancer","volume":"195","author":"Yokomizo","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0092","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1007\/s00345-021-03666-w","article-title":"BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know?","volume":"39","author":"Lebacle","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0093","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.juro.2012.05.015","article-title":"The value of transurethral bladder biopsy after intravesical Bacillus Calmette-Gu\u00e9rin instillation therapy for nonmuscle invasive bladder cancer: a retrospective, single center study and cumulative analysis of the literature","volume":"188","author":"Swietek","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0094","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012227","article-title":"The role of fluorescence in situ hybridization to predict patient response to intravesical Bacillus Calmette-Gu\u00e9rin therapy for bladder cancer: a diagnostic meta-analysis and systematic review","volume":"97","author":"Bao","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clgc.2025.102478_bib0095","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3892\/ol.2016.4556","article-title":"ImmunoCyt test compared to cytology in the diagnosis of bladder cancer: a meta-analysis","volume":"12","author":"HE","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1016\/j.clgc.2025.102478_bib0096","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12894-021-00946-w","article-title":"Comparison between 5-aminolevulinic acid photodynamic diagnosis and narrow-band imaging for bladder cancer detection","volume":"21","author":"Hagimoto","year":"2021","journal-title":"BMC Urology"},{"key":"10.1016\/j.clgc.2025.102478_bib0097","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.3390\/cancers16132299","article-title":"Photodynamic diagnosis and therapy in non-muscle-invasive bladder cancer","volume":"16","author":"Kurabayashi","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2025.102478_bib0098","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2019.01.039","article-title":"The impact of narrow band imaging (NBI) in the detection and resection of bladder tumour in transitional cell carcinoma of the bladder: a prospective, blinded, sequential intervention randomized controlled trial","volume":"128","author":"Mukherjee","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2025.102478_bib0099","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3810\/hp.2013.10.1078","article-title":"Salvage combination intravesical immunotherapy with Bacillus Calmette-Gu\u00e9rin and interferon-\u03b12B: impact on recurrence, progression, and survival","volume":"41","author":"Prasad","year":"2013","journal-title":"Hosp Pract (1995)"},{"key":"10.1016\/j.clgc.2025.102478_bib0100","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bju.13211","article-title":"The effectiveness of BCG and interferon against non-muscle invasive bladder cancer: a New Zealand perspective","volume":"116 Suppl 3","author":"O\u2019Regan","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2025.102478_bib0101","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","article-title":"Salvage intravesical therapy with interferon-alpha 2b plus low dose Bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom Bacillus Calmette-Guerin alone previously failed","volume":"166","author":"O\u2019Donnell","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0102","doi-asserted-by":"crossref","first-page":"458.e1","DOI":"10.1016\/j.urolonc.2023.06.018","article-title":"Sequential intravesical gemcitabine\/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy","volume":"41","author":"Yim","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102478_bib0103","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs Bacillus Calmette-Gu\u00e9rin for the treatment of patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2025.102478_bib0104","article-title":"Intravesical Bacillus Calmette-gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","volume":"1","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clgc.2025.102478_bib0105","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2011.04.023","article-title":"The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review","volume":"60","author":"Lammers","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0106","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3109\/02656736.2016.1141239","article-title":"Overview of bladder heating technology: matching capabilities with clinical requirements","volume":"32","author":"Stauffer","year":"2016","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.clgc.2025.102478_bib0107","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102478_bib0108","unstructured":"Food and Drug Administration, FDA approves first adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Gu\u00e9rin unresponsive non-muscle invasive bladder cancer. (2022) https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-first-adenoviral-vector-based-gene-therapy-high-risk-bacillus-calmette-guerin (Accessed November 12, 2025)."},{"key":"10.1016\/j.clgc.2025.102478_bib0109","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2022.40.16_suppl.4508","article-title":"Final clinical results of pivotal trial of IL-15R\u03b1Fc superagonist n- 803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC)","volume":"40","author":"Chamie","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102478_bib0110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102478_bib0111","article-title":"ALT-803 in the treatment of non-muscle-invasive bladder cancer: preclinical and clinical evidence and translational potential","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.clgc.2025.102478_bib0112","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102478_bib0113","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0114","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3390\/cancers14030694","article-title":"From interferon to checkpoint inhibition therapy-a systematic review of new immune-modulating agents in Bacillus Calmette-Gu\u00e9rin (BCG) refractory non-muscle-invasive bladder cancer (NMIBC)","volume":"14","author":"Deininger","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2025.102478_bib0115","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with Bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0116","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0117","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102478_bib0118","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S0090-4295(03)00236-X","article-title":"Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder","volume":"61","author":"Shariat","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2025.102478_bib0119","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1440-1827.2011.02694.x","article-title":"Association between the expression pattern of p16, pRb and p53 and the response to intravesical Bacillus Calmette-Guerin therapy in patients with urothelial carcinoma in situ of the urinary bladder","volume":"61","author":"Sato","year":"2011","journal-title":"Pathol Int"},{"key":"10.1016\/j.clgc.2025.102478_bib0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3109\/01913123.2012.728688","article-title":"Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy","volume":"37","author":"Ajili","year":"2013","journal-title":"Ultrastruct Pathol"},{"key":"10.1016\/j.clgc.2025.102478_bib0121","doi-asserted-by":"crossref","first-page":"45.e23","DOI":"10.1016\/j.urolonc.2013.06.008","article-title":"Predicting response to Bacillus Calmette-Gu\u00e9rin (BCG) in patients with carcinoma in situ of the bladder","volume":"32","author":"Nunez-Nateras","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102478_bib0122","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-04-0374","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Gu\u00e9rin-induced antitumor activity","volume":"64","author":"Ludwig","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2025.102478_bib0123","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2025.104120","article-title":"Roles for androgen receptor, ADAR2, and PD-L1 in primary urothelial carcinoma in situ of the bladder treated with Bacillus Calmette-Gu\u00e9rin therapy","volume":"105","author":"Ricciardi","year":"2025","journal-title":"Lab Invest"},{"key":"10.1016\/j.clgc.2025.102478_bib0124","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bju.12844","article-title":"The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Gu\u00e9rin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population","volume":"116","author":"Lima","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2025.102478_bib0125","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine panel for response to intravesical therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to Bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Kamat","year":"2016","journal-title":"Eur Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T12:09:50Z","timestamp":1768910990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":125,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1558767325001788"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102478","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urothelial Carcinoma In Situ: Advances in Diagnosis and Management","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102478"}}